Rockwell Medical (RMTI) Q2 2026 Earnings Call Transcript
Rockwell Medical (RMTI) reported Q2 2026 net sales of $17.8 million, up 11% year over year, with gross profit $3.2 million and gross margin expanding to 18%. Net loss improved to $1.2 million, and operating cash flow turned positive at $2.1 million. FY 2026 guidance: revenue $70 million to $75 million, gross margin 18% to 22%, and adjusted EBITDA $1 million to $2 million. The company completed a 1-for-10 reverse split for Nasdaq bid-price compliance.
How this was made
The 30-second read
Why it matters
Traders can update expectations for FY2026 revenue, gross margin, adjusted EBITDA, and operating cash flow based on the company’s stated targets and the cited drivers (automation, new production lines, pricing adjustments, and customer mix).
Market read
The article contains a full set of quarterly datapoints plus explicit FY2026 guidance ranges and operational catalysts, which can drive near-term repricing of the stock’s execution outlook.
What to watch
The reverse stock split to regain Nasdaq bid compliance may affect liquidity and investor positioning, and the guidance depends on continued automation benefits and customer volume stability.
Background
The piece is a transcript-style summary of Rockwell Medical’s Q2 2026 earnings call, including operating metrics, guidance, and operational initiatives.
Ticker impact
Rockwell Medical reported Q2 net sales of $17.8M (+11% YoY), gross margin expansion to 18%, and reiterated FY2026 revenue guidance of $70M to $75M.
Moderately positive bias for the next few sessions as traders price in FY2026 guidance and cash-flow inflection, with volatility around execution risk.
The article provides specific quarterly results plus FY2026 guidance ranges (revenue, gross margin, adjusted EBITDA, and positive operating cash flow) and cites operational drivers (automation, new production lines). That is actionable for positioning, though it is still a transcript-style summary rather than a fresh filing.
Market effects
Dialysis supply chain names may see read-through interest if automation and pricing discipline improve margins across the renal care supplier cohort.
Western U.S. customer growth is highlighted, which could modestly shift attention to regional demand within dialysis services.
Limited, as the article emphasizes a U.S.-centric customer base and international footprint diversification without new international financial disclosures.
Counterpoint
Despite margin improvement, adjusted EBITDA remains negative in Q2 and the FY2026 targets are ranges, so execution risk could cap upside if second-half ramp disappoints.
Key entities
- companyRockwell Medical, Inc.
Reported Q2 2026 results and provided FY2026 guidance, including revenue $70M to $75M and gross margin 18% to 22%.
- executiveMark Strobeck
CEO who discussed strategy pillars and the rationale for the 1-for-10 reverse stock split.
- executiveJesse Neri
CFO who commented on product mix and margin profile, including liquid products in the Western U.S.
